One-Shot gene therapy could slow genetic dementia – first human trial underway
Disease control
Recruiting now
This study tests a new gene therapy called AVB-101 for people with a genetic form of frontotemporal dementia (FTD-GRN). The treatment is given once, directly into the brain, to restore a missing protein and potentially slow or stop the disease. About 18 adults aged 30-75 with ear…
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated May 15, 2026 11:56 UTC